FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) [2016] FCA 1238
File numbers: NSD 763 of 2013
NSD 251 of 2014Judge: NICHOLAS J Date of judgment: 21 October 2016 Catchwords: PATENTS – construction of patent specification describing methods for treating pain comprising administering a therapeutically effective amount of a compound to a mammal in need of said treatment – whether patent obtained by misrepresentation or false suggestion – whether misrepresentation or false suggestion made with respect to compound used in animal tests reported in complete specification – whether misrepresentation or false suggestion was a material inducing factor leading to grant of the patent – whether claims invalid and liable to be revoked on ground that the complete specification does not describe the invention fully – where complete specification does not include any reference to clinical trials involving humans – where complete specification refers only to experiments carried out on rats – whether complete specification provides notional skilled addressee with sufficient information to enable inventive method to be used in the treatment of humans – whether claims invalid and liable to be revoked on ground that the invention claimed is not useful – whether Swiss style claims infringed by importation and sale in Australia of a medicament made outside the patent area – meaning of “exploit” as defined in Schedule 1 of Patents Act 1990 (Cth) Legislation: Patents Act 1990 (Cth) ss 12, 13, 18(1), 22A, 40(2), (3), 120, 138(3), (4)
Patents Act 1952 (Cth) ss 70, 100(1)(k)
Patents Act 1949 (UK) s 32(l)(j)
Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)
Evidence Act 1995 (Cth) s 136
Cases cited: Advanced Building Systems Pty Ltd v Ramset Fasteners (Aust) Pty Ltd (1998) 194 CLR 171
Alphapharm Pty Ltd v H Lundbeck A/S (2008) 76 IPR 618
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) 253 CLR 284
Aristocrat Technologies Australia Pty Ltd v Konami Australia Pty Ltd (2015) 114 IPR 28
AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324
Biogen Inc v Medeva Plc [1997] RPC 1
British Liquid Air Co Ltd v British Oxygen Company Ltd (1908) 25 RPC 577
Electric & Musical Industries Ltd v Lissen Ltd (1938) 56 RPC 23
Eli Lilly and Company v Pfizer Overseas Pharmaceuticals (2005) 64 IPR 506
Eli Lilly & Company v Janssen Alzheimer Immunotherapy [2014] RPC 1
Fawcett v Homan (1896) 13 RPC 398
Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd [2009] RPC 23
Kimberly-Clark Australia Pty Ltd v Arico Trading International Pty Ltd (2001) 207 CLR 1
ICI Chemicals & Polymers Ltd v Lubrizol Corporation Inc (1999) 45 IPR 577
Jupiters Ltd v Neurizon Pty Ltd (2005) 222 ALR 155
Lane Fox v Kensington and Knightsbridge Electric Lighting Co Ltd [1892] 3 Ch 424
Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 217 CLR 274
Merck & Co Inc v Arrow Pharmaceuticals Ltd (2006) 154 FCR 31
Minnesota Mining and Manufacturing Company v Beiersdorf (Australia) Ltd
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2016] FCA 1238
- Decision Date
CaseChat Overview and Summary
The court addressed the validity challenges by first examining the specification's disclosure regarding animal tests and whether it included sufficient information for a notional skilled addressee to replicate the invention in humans. The court considered the relevant fields of expertise, including pharmacology, pharmaceutical formulation, pain medicine, and organic chemistry, and the common general knowledge available at the priority date. The court found that the specification, despite not including human clinical trials, provided enough information for the notional skilled addressee to replicate the invention. Regarding misrepresentation or false suggestion, the court concluded that no material misrepresentation or false suggestion was made with respect to the compound used in animal tests, and thus the patent was not invalid on this ground.
The court also considered whether the complete specification described the invention fully and whether the invention was useful. It found that the complete specification was sufficient, and the invention was useful as it provided a method for treating pain. Finally, the court addressed the issue of infringement under the Swiss-style claims, determining the meaning of "exploit" as defined in the Patents Act 1990 (Cth). The court found that the importation and sale of the medicament did not infringe the claims.
The court rejected all challenges to the validity of the patent claims and granted Warner-Lambert Company LLC quia timet injunctive relief against Apotex and GPPL for threatened infringement. The proceedings were relisted to make final orders, and the parties were directed to file and serve a draft minute of the final orders within 7 days. Certain parts of the reasons for judgment were ordered to be kept confidential.
Orders
Orders of the court
1. The applicants and cross-respondents file and serve a draft minute of the final orders they seek in this proceeding within 7 days.
2. The proceeding stand over to a date to be fixed for the purpose of making final orders.
3. Up to and including 28 October 2016 or further order, the contents of paragraphs [275] to [281] (inclusive) and [283] of the reasons for judgment of Nicholas J dated today be kept confidential and not be made available for public inspection.
4. There be liberty to apply on 24 hours’ notice.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.